Halozyme Therapeutics, INC Form 4 insider transactions

Michael J. LaBarre, SVP and Chief Technical Officer of Halozyme Therapeutics, reports the vesting and settlement of restricted stock units and associated tax withholding.

Mark Howard Snyder, SVP, Chief Legal Officer of Halozyme Therapeutics, reports the vesting and settlement of restricted stock units and associated tax withholding.

Nicole LaBrosse, SVP and CFO of Halozyme Therapeutics, reports the vesting and settlement of restricted stock units and associated tax withholding.

Helen Torley, President and CEO of Halozyme Therapeutics, reports the vesting and settlement of restricted stock units and related tax withholding.

Michael J. LaBarre, SVP, Chief Technical Officer of Halozyme Therapeutics, reports the acquisition of stock options and restricted stock units.

Mark Howard Snyder, SVP, Chief Legal Officer of Halozyme Therapeutics, reports the acquisition of stock options and restricted stock units.

Nicole LaBrosse, CFO of Halozyme Therapeutics, reports the acquisition of stock options and restricted stock units.

Halozyme Therapeutics' CEO, Helen Torley, reports acquisition of stock options and restricted stock units.

Michael J. LaBarre, SVP and Chief Technical Officer of Halozyme Therapeutics, exercised stock options and sold shares to cover tax withholding obligations.

Mark Howard Snyder, SVP and Chief Legal Officer of Halozyme Therapeutics, reports the vesting and settlement of performance and restricted stock units, along with associated tax withholding dispositions.

Nicole LaBrosse, CFO of Halozyme Therapeutics, reports the vesting and settlement of restricted and performance stock units, along with associated tax withholding obligations.

Halozyme Therapeutics' CEO, Helen Torley, reports the vesting and settlement of restricted and performance stock units, along with associated tax withholding dispositions.

Michael J. LaBarre, SVP and Chief Technical Officer of Halozyme Therapeutics, received performance-based stock units that vested based on performance ending December 31, 2024, subject to continued service.

Mark Howard Snyder, SVP and Chief Legal Officer of Halozyme Therapeutics, reports the acquisition and disposal of performance stock units (PSUs) based on performance measurements ending December 31, 2024.

Nicole LaBrosse, CFO of Halozyme Therapeutics, reports the acquisition of performance-based stock units that will vest based on continued service.

Halozyme Therapeutics' CEO, Helen Torley, acquired performance-based vesting stock units based on performance achieved during the period ending December 31, 2024.

Jeffrey William Henderson, a director at Halozyme Therapeutics, sold shares of common stock on February 3, 2025, under a pre-arranged trading plan.

Jeffrey William Henderson, a director at Halozyme Therapeutics, sold 10,000 shares of common stock at an average price of $50.006 per share on January 6, 2025, under a pre-arranged trading plan.

Mark Howard Snyder, SVP, Chief Legal Officer of Halozyme Therapeutics, reports the vesting and settlement of restricted stock units and associated tax withholding.

Director Connie Matsui of Halozyme Therapeutics reported a gift of 10,470 common stock shares to charity.

Halozyme Therapeutics CEO Helen Torley gifted 10,000 shares of common stock to charity on November 29, 2024.

Michael J. LaBarre, SVP, Chief Technical Officer of Halozyme Therapeutics, reports multiple transactions involving company stock, including option exercises and sales, executed under a pre-arranged Rule 10b5-1 trading plan.

Halozyme Therapeutics' CEO, Helen Torley, executed option exercises and subsequent stock sales under a pre-arranged trading plan.

Halozyme Therapeutics' CEO, Helen Torley, executed stock options and sold shares between September 24 and September 26, 2024, under a pre-arranged trading plan.

Michael J. LaBarre, SVP, Chief Technical Officer of Halozyme Therapeutics, executed option exercises and sales of common stock under a pre-arranged Rule 10b5-1 trading plan.

Halozyme Therapeutics CEO Helen Torley exercised stock options and sold shares between September 10 and September 12, 2024, under a pre-arranged trading plan.

Michael J. LaBarre, SVP and Chief Technical Officer of Halozyme Therapeutics, exercised options to purchase 5,580 shares of common stock at $18.41 on August 27, 2024.

Michael J. LaBarre, SVP, Chief Technical Officer of Halozyme Therapeutics, executed option exercises and sales of common stock under a pre-arranged 10b5-1 trading plan.

Halozyme Therapeutics CEO Helen Torley exercised stock options and sold shares between August 13 and August 15, 2024, under a pre-arranged trading plan.

Director Matthew L. Posard of Halozyme Therapeutics, Inc. [HALO] executed multiple sales of common stock between August 12 and August 14, 2024, reducing his holdings.